NES, NoMAC and DRSP inhibit the activity of human 3βHSD2, while only DRSP inhibits CYP17A1 activity.

<p>COS-1 cells were transiently transfected with plasmids expressing human (A) 3βHSD2 (pCDNA6-hHSD3β2-V5), (B) CYP17A1 (pIRES-hCYP17A1-V5-X-hCYPB5-6HIS) or (C and D) CYP21A2 (pCDNA6-hCYP21A2-V5), respectively. Cells were subsequently treated with 1 μM Preg (A) or Prog (B and C) or 17OH-Prog (D), in the absence (DMSO) and presence of 1 μM MPA, LNG, GES, NES, NoMAC or DRSP for 20 minutes (A), 4 hours (B) or 90 minutes (C and D), respectively. The steroid metabolites produced by the cells in the medium were extracted and analyzed by UPLC–MS/MS. The concentration of the steroids produced by the cells was normalized to the total protein concentration using the Bradford protein assay method. The % conversion of substrate to product was plotted, with the substrate only response (DMSO) set as 100% and everything else relative to that. Results shown are the average of at least two independent experiments with each condition performed in triplicate (± SEM).</p

Effect of selected progestins on total steroid production by the human H295R adrenocortical carcinoma cell line under basal and FSK-stimulated conditions.

<p>Cells were incubated with DMSO (vehicle control) or 1 μM MPA, NET-A, LNG, GES, NES, NoMAC or DRSP, in the absence and presence of 10 μM FSK for 48 hours. Steroid metabolites were extracted from the cell culture medium and analyzed by UPLC–MS/MS. The concentrations of total steroid produced (μM) were normalized to protein concentration (mg/ml). The insert graph shows the total steroid production (μM/mg protein) in the absence of progestin treatment (DMSO) under basal and FSK-stimulated conditions. This total steroid production for both conditions was set as 100%, and the percentage change upon treatment with progestin relative to the vehicle control (DMSO) of each condition was plotted. Results shown are the average of three independent experiments with each condition performed in triplicate (± SEM).</p

Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids

<div><p>Progestins used in contraception and hormone replacement therapy are synthetic compounds designed to mimic the actions of the natural hormone progesterone and are classed into four consecutive generations. The biological actions of progestins are primarily determined by their interactions with steroid receptors, and factors such as metabolism, pharmacokinetics, bioavailability and the regulation of endogenous steroid hormone biosynthesis are often overlooked. Although some studies have investigated the effects of select progestins on a few steroidogenic enzymes, studies comparing the effects of progestins from different generations are lacking. This study therefore explored the putative modulatory effects of progestins on <i>de novo</i> steroid synthesis in the adrenal by comparing the effects of select progestins from the respective generations, on endogenous steroid hormone production by the H295R human adrenocortical carcinoma cell line. Ultra-performance liquid chromatography/tandem mass spectrometry analysis showed that the fourth-generation progestins, nestorone (NES), nomegestrol acetate (NoMAC) and drospirenone (DRSP), unlike the progestins selected from the first three generations, modulate the biosynthesis of several endogenous steroids. Subsequent assays performed in COS-1 cells expressing human 3βHSD2, suggest that these progestins modulate the biosynthesis of steroid hormones by inhibiting the activity of 3βHSD2. The K_i values determined for the inhibition of human 3βHSD2 by NES (9.5 ± 0.96 nM), NoMAC (29 ± 7.1 nM) and DRSP (232 ± 38 nM) were within the reported concentration ranges for the contraceptive use of these progestins <i>in vivo</i>. Taken together, our results suggest that newer, fourth-generation progestins may exert both positive and negative physiological effects via the modulation of endogenous steroid hormone biosynthesis.</p></div

NES, NoMAC and DRSP do not inhibit the mRNA expression of <i>3βHSD2</i> and <i>CYP17A1</i> in the human H295R adrenocortical carcinoma cell line.

<p>The H295R cell line was incubated with DMSO (vehicle control) or 1 μM NES, NoMAC or DRSP for 6 hours. Total RNA was isolated, reversed transcribed to cDNA and real-time qPCR performed to determine the relative mRNA expression levels of (A) <i>3βHSD2</i> and (B) <i>CYP17A1</i>. <i>GAPDH</i> was used as the reference gene. Results shown are the average of four independent experiments with each condition performed in duplicate (± SEM).</p

The biosynthesis of human steroid hormones consists of multiple reactions which are catalysed by specific steroidogenic enzymes (grey boxes).

<p>The conversion of 17α-hydroxyprogesterone (17OH-Prog) to androstenedione (A4) by CYP17A1 is shown as a dashed box as 17OH-Prog is a poor substrate for the 17,20-lyase activity of human CYP17A1 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164170#pone.0164170.ref022" target="_blank">22</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164170#pone.0164170.ref031" target="_blank">31</a>].</p

Fold change in FSK-stimulated steroid production in response to selected progestins^b.

<p>Fold change in FSK-stimulated steroid production in response to selected progestins<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164170#t002fn001" target="_blank">^b</a>.</p

Inhibition of 3βHSD2 activity by NES, NoMAC, DRSP and trilostane.

<p>COS-1 cells were transiently transfected with a plasmid expressing human 3βHSD2 (pCDNA6-hHSD3β2-V5), and subsequently treated with increasing concentrations (0.5, 1, 2, 4 and 8 μM) of Preg (substrate) in the presence of 0.0, 0.2 or 0.5 μM (A) NES, (B) NoMAC, (C) DRSP or (D) trilostane. The conversion of Preg to Prog was analyzed using UPLC-MS/MS. Michaelis-Menten plots are shown in the absence (black symbols and lines) and presence of 0.2 μM (red symbols and lines) and 0.5 μM (blue symbols and lines) of NES, NoMAC, DRSP and trilostane. A K_m of 0.85 ± 0.05 μM and V_max of 31.1 ± 0.7 nmol/min/mg were obtained in the absence of inhibitor. Three inhihitory mechanisms were fitted (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164170#pone.0164170.s002" target="_blank">S2 Fig</a>) and the best fit mechanism is shown. Each data point represents the mean ± SE of one experiment performed in duplicate. These results were validated by a model predicting 3βHSD2 activity in an independent experiment (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164170#pone.0164170.s003" target="_blank">S3 Fig</a>, dashed green line).</p

Chemical structures of the endogenous steroids progesterone (Prog) and testosterone, the synthetic MR antagonist spironolactone, and the progestins used in this study

<p>: Medroxyprogesterone acetate (MPA), nestorone (NES), nomegestrol acetate (NoMAC), norethisterone/norethindrone acetate (NET-A), levonorgestrel (LNG), gestodene (GES) and drospirenone (DRSP). The inserts (1^st, 2^nd, 3^rd and 4^th) denote the four consecutive generations of progestins.</p

Fold change in basal steroid production in response to selected progestins^a.

<p>Fold change in basal steroid production in response to selected progestins<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164170#t001fn001" target="_blank">^a</a>.</p

The policy, infrastructure, training, and funding landscape of computational biology in South Africa (2000–present).

<p>Government policy on computational biology was driven largely by the DST (above timeline arrow), while bioinformatics training courses have been a constant feature of this landscape since 2003. There was a major period of infrastructure investment from 2002–2007, from the NBN, but national funding has now become available only every two years. National bioinformatics conferences also occur in two-year intervals (details in text).</p